SMAD5 is a receptor-regulated transcriptional mediator that transduces bone morphogenetic protein (BMP) and transforming growth factor-β (TGF-β) signaling. Upon BMP ligand binding, SMAD5 is phosphorylated by type I BMP receptors, associates with SMAD4, and translocates to the nucleus where the complex recognizes Smad Binding Elements to regulate gene expression 1. SMAD5 controls diverse biological processes including embryonic development, cell differentiation, osteoblast differentiation, and angiogenesis. Beyond its canonical nuclear role, non-phosphorylated SMAD5 regulates energy metabolism by promoting mitochondrial respiration and glycolysis through direct interaction with hexokinase 1 2. SMAD5 exhibits unique nuclear-cytoplasmic shuttling properties responsive to intracellular pH changes, distinguishing it from related Smad proteins 2. Dysregulation of SMAD5 is implicated in multiple pathologies: it suppresses intestinal fibrosis through BMP-7 activation 3, modulates granulosa cell apoptosis via the FasL-Fas pathway 4, and promotes osteogenic differentiation of stem cells 5. In hepatocellular carcinoma, SMAD5 undergoes gene amplification and upregulation rather than loss, suggesting oncogenic rather than tumor-suppressor roles 6. Recent evidence demonstrates SMAD5's involvement in stromal reprogramming within pancreatic cancer, where TGF-β-SMAD5 signaling regulates branched-chain amino acid metabolism 7.